What disease does fezolinetant treat?

Fezolinetant is a neurokinin 3 (NK3) receptor antagonist, mainly used to treat moderate to severe vasomotor symptoms caused by menopause, especially typical symptoms such as hot flashes. Hot flashes are one of the common symptoms of menopausal women. They usually manifest as facial flushing, sweating, rapid heartbeat and other discomforts. In severe cases, they can affect the quality of daily life and even cause emotional instability and sleep problems.

During menopause, changes in hormone levels in women, especially the decline in estrogen, lead to disorders in the hypothalamus’ control of body temperature regulation, which in turn triggers vasomotor symptoms such as hot flashes. Fezonatant regulates the activity of neurotransmitters in the body and relieves symptoms such as hot flashes by binding to neurokinin 3 (NK3) receptors. The NK3 receptor is a key biological target involved in the regulation of body temperature and vasomotion. Therefore, by antagonizing this receptor, fezonatant can effectively reduce the vasomotor symptoms caused by menopause.

Different from traditional hormone replacement therapy (HRT), as a non-hormonal drug, filazonatant avoids the possible side effects of hormone therapy, such as the risk of breast cancer and endometrial cancer. Therefore, it provides a new treatment option for women who are unable or unwilling to use hormone therapy. Especially for patients with a history of hormone-dependent diseases, filzonetam is particularly important.

Fezonatant has significant efficacy in treating moderate to severe hot flashes, and clinical trials have shown that patients using the drug experienced significant relief in the frequency and severity of hot flashes. Compared with other drugs of the same type, Fezonaitan has a longer-lasting effect on relieving menopausal symptoms and has relatively few side effects. Its safety, especially in long-term use, has been fully verified.

Reference: https://www.astellas.com/content/dam/astellas-com/global/en/documents/veozah_usppi.pdf